New therapies for diabesity

详细信息    查看全文

• 作者：Clifford J. Bailey (1)
  
• 刊名：Current Diabetes Reports
• 出版年：2009
• 出版时间：October 2009
• 年：2009
• 卷：9
• 期：5
• 页码：360-367
• 全文大小：307KB
• 参考文献：1. Bailey CJ: Drugs on the horizon for diabesity. / Curr Diab Rep 2005, 5:353-59. CrossRef
  2. Shafrir E: Animal models for non-insulin-dependent diabetes. / Diabetes Metab Rev 1992, 8:179-08. CrossRef
  3. Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. / Nature 2006, 444:840-46. CrossRef
  4. Montague CT, O’Rahilly S: The perils of portliness. Causes and consequences of visceral adiposity. / Diabetes 2000, 49:883-88. CrossRef
  5. Maggio CA, Pi-Sunyer FX: Obesity and type 2 diabetes. / Endocrinol Metab Clin North Am 2003, 32:805-22. CrossRef
  6. Aucott L, Poobalan A, Smith WC, et al.: Weight loss in obese diabetic and non-diabetic individuals and long-tem diabetes outcomes—a systematic review. / Diabetes Obes Metab 2004, 6:85-4. CrossRef
  7. Krentz AJ, Bailey CJ: Oral antidiabetic agents: current role in type 2 diabetes mellitus. / Drugs 2005, 65:385-11. CrossRef
  8. Bailey CJ, Day C: Fixed-dose single tablet antidiabetic combinations. Whence and whither the fixed-dose combination? / Diabetes Obes Metab 2009, 11:527-33. CrossRef
  9. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. / BMJ 2003, 326:1419-423. CrossRef
  10. Holst JJ: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. / Diabetologia 2006, 49:253-60. CrossRef
  11. Gentilella R, Bianchi C, Rossi A, Rotella CM: Exenatide: a review from pharmacology to clinical practice. / Diabetes Obes Metab 2009, 11:544-56. CrossRef
  12. Garber A, Henry R, Ratner R, et al.: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. / Lancet 2009, 373:473-81. CrossRef
  13. Flatt PR, Bailey CJ, Green BD: Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. / Curr Drug Metab 2009, 10:125-37. CrossRef
  14. Pan CQ, Buxton JM, Yung SL, et al.: Design of a long-acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. / J Biol Chem 2006, 281:12506-2515. CrossRef
  15. Chen D, Liao J, Li N, et al.: A nonpeptidic agonist of glucagon-like peptide-1 receptors with efficacy in diabetic db/db mice. / Proc Natl Acad Sci U S A 2007, 104:943-48. CrossRef
  16. Knudsen LB, Kiel D, Teng M, et al.: Small-molecule agonists for the glucagon-like peptide 1 receptor. / Proc Natl Acad Sci U S A 2007, 104:937-42. CrossRef
  17. Flatt PR: Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? / Diabet Med 2008, 25:759-64. CrossRef
  18. Irwin N, McClean PL, O’Harte FP, et al.: Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. / Diabetologia 2007, 50:1532-540. CrossRef
  19. Flatt PR, Bailey CJ, Green BD: Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. / Front Biosci 2008, 13:3648-660. CrossRef
  20. Berger JP, Akiyama TE, Meinke PT: PPARs: therapeutic targets for metabolic disease. / Trends Pharmacol Sci 2005, 26:244-51. CrossRef
  21. Quinn CE, Hamiltoon PK, Lockhart CJ, McVeigh GE: Thiazolidinediones: effects on insulin resistance and cardiovascular system. / Br J Pharmacol 2008, 153:636-45. CrossRef
  22. Gross B, Staels B: PPAR agonists: multimodal drugs for the treatment of type 2 diabetes. / Clin Endocrinol Metab 2007, 21:687-10.
  23. Allen T, Zhang F, Moodle SA, et al.: Halofenate is a selective peroxisome proliferators-activated receptor gamma modulator with antidiabetic activity. / Diabetes 2006, 55:2523-533. CrossRef
  24. Puigserver P, Spegelman BM: Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha): transcriptional coactivator and metabolic regulator. / Endocr Rev 2003, 24:78-0. CrossRef
  25. Conlon D: Goodbye glitazars? / Br J Diabetes Vasc Dis 2006, 6:135-37. CrossRef
  26. Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. / Nat Med 2004, 10:1-. CrossRef
  27. Jabbour SA, Goldstein BJ: Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. / Int J Clin Pract 2008, 62:1279-284. CrossRef
  28. Bailey CJ, Gross JL, Bastone L, et al.: Dapagliflozin as an add-on to metformin lowers hyperglycaemia in type 2 diabetes patients inadequately controlled with metformin alone. / Diabetologia 2009, 52:A169. CrossRef
  29. Zhang B, Salituro G, Szalkowski D, et al.: Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. / Science 1999, 284:974-77. CrossRef
  30. Koren S, Fantus IG: Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type 2 diabetes mellitus. / Clin Endocrinol Metab 2007, 21:621-40.
  31. Bailey CJ: Treating insulin resistance: future prospects. / Diabetes Vasc Dis Res 2007, 4:20-1. CrossRef
  32. Matschinsky FM, Magnuson MA, Zelent D, et al.: The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. / Diabetes 2006, 55:1-2. CrossRef
  33. Agius L: New hepatic targets for glycaemic control in diabetes. / Clin Endocrinol Metab 2007, 21:587-06.
  34. Schimmack G, DeFronzo RA, Musi N: AMP-activated protein kinase: role in metabolism and therapeutic implications. / Diabetes Obes Metab 2006, 8:591-02. CrossRef
  35. Rivera N, Everett-Grueter CA, Edgerton DS, et al.: A novel glucagon receptor antagonist, NNC 15-0926, blunts hepatic glucose production in the conscious dog. / J Pharm Exp Ther 2007, 321:743-52. CrossRef
  36. Jacobson PB, von Geldern TW, Ohman L, et al.: Hepatic glucocorticoid antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. / J Pharm Exp Ther 2005, 314:191-00. CrossRef
  37. Tomlinson JW, Stewart PM: Modulation of glucocorticoid action and the treatment of type 2 diabetes. / Clin Endocrinol Metab 2007, 21:607-19.
  38. Pijl H, Ohashi S, Matsuda M, et al.: Bromocriptine: a novel approach to the treatment of type 2 diabetes. / Diabetes Care 2000, 23:1154-61. CrossRef
  39. Bailey CJ: New drugs for the treatment of diabetes mellitus. In / International Textbook of Diabetes Mellitus, edn 3. Edited by DeFronzo RA, Ferrannini E, Keen H, Zimmet P. Chichester: John Wiley; 2004:951-80.
  40. Di Marzo V: The endocannabinoid system in obesity and type 2 diabetes. / Diabetologia 2008, 51:1356-367. CrossRef
  41. Rosenstock J, Hollander P, Chevalier S, et al.: The Serenade trial: effect of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-na?e type 2 diabetes. / Diabetes Care 2008, 31:2169-176. CrossRef
  42. Christensen R, Kristensen P, Bartels EM, et al.: Efficacy and safety of the weight loss drug rimonabant: a meta-analysis of randomised trials. / Lancet 2007, 370:1706-713. CrossRef
  43. Day C, Bailey CJ: Pharmacological approaches to reduce adiposity. / Br J Diabetes Vasc Dis 2006, 6:121-25. CrossRef
  44. Kruger DF, Gloster MA: Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. / Drugs 2004, 64:1419-432. CrossRef
  45. Bailey CJ, Day C: New pharmacological approaches to obesity. / Obes Pract 2005, 1:2-.
  46. Billyard T, McTernan P, Kumar S: Potential therapies based on antidiabetic peptides. / Clin Endocrinol Metab 2007, 21:641-55.
  47. Kadowski T, Yamauchi T: Adiponectin and adiponectin receptors. / Endocr Rev 2005, 26:439-51. CrossRef
  48. Graham TE, Yang Q, Bluher M, et al.: Retinal binding protein 4 and insulin resistance in lean, obese and diabetic subjects. / N Engl J Med 2006, 354:2552-563. CrossRef
  49. Lavu S, Boss O, Elliott PJ, Lambert PD: Sirtuins: novel therapeutic targets to treat age-associated diseases. / Nat Rev Drug Discov 2008, 7:841-53. CrossRef
  50. Milne JC, Lambert PD, Schenk S, et al.: Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. / Nature 2007, 450:712-16. CrossRef
  
• 作者单位：Clifford J. Bailey (1)
  
  1. Life and Health Sciences, Aston University, Aston Street, Aston Triangle, Birmingham, B4 7ET, UK
  

文摘

Many patients with type 2 diabetes are obese (diabesity), and the two conditions together impose a particularly complex therapeutic challenge. Several differently acting agents are often required at the same time, encouraging development of more single-tablet combinations. Longer-acting (once daily and once weekly) injected agonists of glucagon-like peptide-1 are due to provide additional options to stimulate insulin secretion with weight loss and minimal risk of hypoglycemia. Further, dipeptidyl peptidase-4 inhibitors (“weight-neutral-insulinotropic agents) are also expected. Sodium-glucose cotransporter 2 inhibitors offer a new option to reduce hyperglycemia and facilitate weight loss by increasing the elimination of glucose in the urine. Selective peroxisome proliferator-activated receptor modulators are being studied to produce compounds with desired effects. Many other agents with antidiabetic and antiobesity activity are progressing in clinical development.